Answers are grounded in this paper and cite their sources.
Multiple system atrophy (MSA) remains one of the most challenging neurodegenerative disorders to diagnose, clinically characterized by various combinations of levodopa-resistant parkinsonism, cerebellar, autonomic, and pyramidal dysfunction. Early diagnosis of this disease is challenging, with post-mortem studies showing that the accuracy of diagnosis is only 62-79%. Late diagnosis is common, with an average of 3-4 years from the onset of the first symptoms to diagnosis. Given that the average survival is about 7-9 years, early diagnosis is crucial for the patient's quality of life and effective treatment. This article provides a comprehensive analysis of three distinct clinical cases (MSA-P, MSA-C, and Mixed phenotype), highlighting the critical role of the 2022 Movement Disorder Society (MDS) diagnostic criteria in refining clinical accuracy, offers a practical framework for clinicians to improve early detection and symptomatic management of MSA, ultimately aiming to enhance patient quality of life in the absence of a curative therapy.
No takes yet. Share an insight, caveat, or question.
Karzhaubayeva et al. (2026) studied this question.